Selected article for: "Coronavirus SARS CoV and economic burden"
Author: Ellinger, Bernhard; Bojkova, Denisa; Zaliani, Andrea; Cinatl, Jindrich; Claussen, Carsten; Westhaus, Sandra; Keminer, Oliver; Reinshagen, Jeanette; Kuzikov, Maria; Wolf, Markus; Geisslinger, Gerd; Gribbon, Philip; Ciesek, Sandra
Title: A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection
  • Cord-id: 27x19u87
  • Document date: 2021_2_26
    • ID: 27x19u87
    Snippet: SARS-CoV-2 is a novel coronavirus responsible for the COVID-19 pandemic, in which acute respiratory infections are associated with high socio-economic burden. We applied high-content screening to a well-defined collection of 5632 compounds including 3488 that have undergone previous clinical investigations across 600 indications. The compounds were screened by microscopy for their ability to inhibit SARS-CoV-2 cytopathicity in the human epithelial colorectal adenocarcinoma cell line, Caco-2. The
    Document: SARS-CoV-2 is a novel coronavirus responsible for the COVID-19 pandemic, in which acute respiratory infections are associated with high socio-economic burden. We applied high-content screening to a well-defined collection of 5632 compounds including 3488 that have undergone previous clinical investigations across 600 indications. The compounds were screened by microscopy for their ability to inhibit SARS-CoV-2 cytopathicity in the human epithelial colorectal adenocarcinoma cell line, Caco-2. The primary screen identified 258 hits that inhibited cytopathicity by more than 75%, most of which were not previously known to be active against SARS-CoV-2 in vitro. These compounds were tested in an eight-point dose response screen using the same image-based cytopathicity readout. For the 67 most active molecules, cytotoxicity data were generated to confirm activity against SARS-CoV-2. We verified the ability of known inhibitors camostat, nafamostat, lopinavir, mefloquine, papaverine and cetylpyridinium to reduce the cytopathic effects of SARS-CoV-2, providing confidence in the validity of the assay. The high-content screening data are suitable for reanalysis across numerous drug classes and indications and may yield additional insights into SARS-CoV-2 mechanisms and potential therapeutic strategies.

    Search related documents:
    Co phrase search for related documents
    • accession number and action mechanism: 1
    • accession number and acute sars cov respiratory syndrome coronavirus: 1, 2, 3
    • accession number and lung epithelium: 1
    • ace inhibitor and action mechanism: 1, 2, 3, 4
    • ace inhibitor and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • ace inhibitor and lung epithelium: 1, 2
    • action mechanism and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • action mechanism and additional study: 1
    • action mechanism and low concentration: 1, 2, 3, 4
    • action mechanism and low cytotoxicity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • action mechanism and low toxicity: 1, 2, 3, 4, 5, 6, 7
    • action mechanism and lung epithelium: 1
    • action possible mechanism and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8
    • action site and acute sars cov respiratory syndrome coronavirus: 1
    • action site and low concentration: 1